71 results about "Healthy volunteers" patented technology

The present invention provides pharmaceutical release systems comprising an therapeutically effective amount of flibanserin and at least one pharmaceutically acceptable excipient, characterized in that said pharmaceutical release systems exhibit a pharmacokinetic profile that is characterized by an average maximum flibanserin plasma concentration Cmax lower than 300 ng / mL, preferably lower than 200 ng / mL after administration of a single dose to healthy volunteers in fasted state or directly after a meal.

The invention discloses certain mycobacterium tuberculosis specific antigen epitope polypeptides, and particularly discloses an antigen Pv3615c antigen epitope polypeptide consisting of 8-11 continuous polypeptide fragments. The clinical detection practicability of the antigen polypeptide is evaluated according to the reaction sensitivity and specificity of the antigen polypeptide in a tuberculosis case. As proved by a result, an antigen polypeptide has high T cell reactivity in a tuberculosis patient, and the positive rate is up to 64 percent (9 / 14). Compared with the result of a healthy volunteer, the antigen epitope polypeptide has the specificity of up to 100 percent (6 / 6). Mycobacterium tuberculosis infection can be diagnosed effectively by applying an antigen peptide library specific T cell gamma interferon.

Impedance spectroscopy has been proposed as a method of monitoring mucosal injury due to hypoperfusion and ischemia in the critically ill. The invention includes an algorithm developed to calculate the characteristic electrical values that best describe human gastric impedance measurements and simplify the information obtained with this method. A database of gastric spectra was obtained from healthy volunteers, cardiovascular surgery and critically ill patients. The gastric spectrum forms two semi circles in the complex domain, divided into low frequency (F<10 kHz) and high frequency (F>10 kHz). A fitting algorithm was developed based on the Cole model, and central characteristic parameters were calculated. The parameters were validated using the normalized mean squared error and 0.7% of the spectra were discarded. From the experimental data obtained in humans, the greatest changes observed as the gastric mucosa becomes ischemic occur at low frequencies, which are specific and sensitive to tissue damage, and vary with the degree of hypoperfusion.

The invention discloses HLA-A2 restrictive epitope polypeptide of an LMP2A protein source, which is polypeptide LMP2A264 and comprises 9 amino acids in the positions of 264 to 272; the sequence is QLSPLLGAV. Mycobacteria heat shock protein 70 (HSP70) is expressed, identified and purified; a transgene animal model for evaluating EBV relevant polypeptide vaccine in vivo tests is established; the immune research on inducing EBV specific CTL inside and outside healthy volunteers and transgene rats for the new EBV epitope polypeptide LMP2A264 is systemically researched and the tumor prevention andthe tumor treating test of the polypeptide LMP2A264 on LMP2A positive solid tumors are evaluated, thereby proving that the polypeptide LMP2A264 can induce LMP2A specific cell toxic T lymphocyte reaction. Therefore, the polypeptide LMP2A264 can be applied to prepare medicaments for treating or preventing LMP2A positive solid tumors.

The invention discloses a method and device for detecting body haemodynamics response in in-vitro counterpulsation treatment. The detection method comprises the steps that physiological information ofa sampler is acquired, and blood vessel and blood flow state data before and in in-vitro counterpulsation treatment are acquired respectively; an arterial tree is segmented based on an arterial treestructure model, blood segment length and radius data of a healthy volunteer are acquired, a baseline reference value is set, and an arterial tree geometric solution model is constructed; and boundaryconditions and correction and calibration conditions are calculated and set, flow and pressure pulse wave distribution of each position of the arterial tree is calculated on the basis of the pulse wave transmission theory and the model, and the blood perfusion and blood pressure levels of target blood vessel segments and visceral organs before and in the in-vitro counterpulsation treatment are calculated. The method and device can be used for noninvasive, real-time and effective analysis of the immediate haemodynamics effect of the in-vitro counterpulsation intervention treatment, and break the technical bottleneck of lack of an effective immediate haemodynamics effect evaluation method in the current in-vitro counterpulsation treatment.

The present invention relates to a plasma biomarker for diagnosing hepatocellular carcinoma (HCC), in particular to the discovery of a protein in plasma using 2-D fluorescence differential gel electrophoresis (2-D DIGE), immunoprecipitation and Nano-liquid chromatography mass spectrometry (Nano-LC-MS / MS) system that was unknown on the basis of conventional techniques. By demonstrating the presence of liver carboxylesterase 1 (hCE1) in human plasma and confirming that its secretion level is higher in patients with HCC than in healthy volunteers, this invention may be used as a screening method to diagnose HCC at an early stage.

The invention discloses a nutritional strengthening wheat germ low calorie meal-instead food, which takes water-soluble wheat germ as matrix, and strengthens nutrients as protein, vitamin, minerals and l-carnitine and the like, and has the characteristic of low calorie and special functions of controlling the velocity of energy metabolism in bodies and providing satiety and the like, and is capable of instead of dinners. The invention reduces energy intake, simultaneously, guarantees the health of human bodies, and promoting the transformation of retention fat in the human bodies. Through eating tests of healthy volunteers whose ages are 21-24 years and body mass index is 20.4-25.4, after eating the meal-instead food, the average time of producing hunger feeling is 3.5-3.8 hours, and the time is accord with normal interval of the time of dining of normal population.

The invention relates to the technical field of genetic engineering, in particular a method for constructing a natural humanized IgG Fab phage antibody library. In the method, Fd genes of the whole set of humanized antibody light chains and antibody heavy chains are amplified from peripheral blood lymphocyte of healthy volunteers by DNA recombinant technology, and are inserted into corresponding positions of phage vector pFabICN so as to construct the natural humanized IgG Fab phage antibody library with high capacity and high variety. Experiments prove that the capacity of the phage antibody library constructed by the method can reach as high as 4*108; and the phage antibody library accords with high-capacity antibody library standard, includes Fd genes of the whole set of humanized antibody light chains and heavy chains, and has high variety. Compared with other phage antibody library constructing methods, the antibody library constructed by the method has the advantages of high capacity and high variety, can be used in low-antigenicity high-compatibility humanized antibody for high-flux screening clinical treatment.

Hematopoietic stem cells of healthy volunteers are separated and purified in a 100 grade GMP (Good Manufacturing Practice) plant, and are induced to divide to NK cells under a special condition of culture. Qualified NK cells are put in storage or KIR-matched with HLA (Human Leukocyte Antigen) and KN cells of the patients. The qualified NK cells are intravenously infused to tumor patients to prevent recurrence and metastasis of cancer cells of the tumor patients. The hematopoietic stem cells used by the method have the advantages of abundant source, material object storage and the like, are free from toxic and side effects and adverse reaction for treating tumor, and remarkably improve the survival quality of the tumor patients.

The invention discloses a myocardial excitation contraction coupling time diagnostic apparatus and application thereof. The diagnostic apparatus provided by the invention comprises an electrocardio collection unit, an ultrasonic heartbeat collection unit, an analysis processing unit and a data output unit, wherein the electrocardio collection unit is used for defecting myocardial electrical excitation; the ultrasonic heartbeat collection unit is used for detecting myocardial contraction; the analysis processing unit is used for recording the starting time of the myocardial electrical excitation detected by the electrocardio collection unit and the starting time of the myocardial contraction detected by the ultrasonic heartbeat collection unit and analyzing the time interval between the starting time of the myocardial electrical excitation and the starting time of the myocardial contraction; and the data output unit is used for outputting data obtained by the analysis processing unit. Experiments prove that the coupling delay time of the heart failure patients is markedly longer than that of the healthy volunteers so that the coupling delay time displayed by the diagnostic apparatus disclosed by the invention can be used for evaluating the heart function.

The invention relates to a making method of a human intestinal micro-ecological system. The human intestinal micro-ecological system cultured by a chemostat is used to prevent and treat infectious diseases, the self-made chemostat is used to culture healthy volunteers having no antibiotic history within three months, and the human intestinal micro-ecological system is used for treating enrofloxacin infections diseases. Compared with single or several probiotic combination, the human intestinal micro-ecological system directly treating the whole micro-ecological system of the healthy volunteers as an integral body to prevent and treat diseases has the advantages stable composition, strong anti-interference ability and good treatment effect; and additionally, the micro-ecological system used in the invention originates from the human body, so the cultured micro-ecological system is safe to human bodies, and has no toxic side effects.

The invention relates to a method for purifying stem cells by utilizing adipose tissues obtained during the weight-loss liposuction of a healthy volunteer for breast augmentation and wrinkle removal. The method comprises the following operation steps of: (1) collecting the adipose tissues; (2) digesting the adipose tissues; (3) purifying the adipose tissues; (4) purifying adipose-derived stem cells; (5) carrying out amplification culture on the adipose-derived stem cells; (6) freezing the stem cells for storage. The ADSCs (Adipose-Derived Stem Cells) obtained through extraction and purification under the condition that a GMP (Good Manufacturing Practice) workshop is sterile has multiple advantages for the breast augmentation or face wrinkle removal: the ADSCs can be stably proliferated in vitro, is low in mortality rate, less in damage on a machine body during transplantation, wide in material source and good in breast augmentation effect, can achieve ideal wrinkle removing effect through a small quantity of cells, is safe and reliable without rejection and can provide a good method for augmenting breasts and restoring the skin elasticity of adolescence.

An orally taken medicinal composition of thymosin alpha 1 carried by microspheres features that it can be located in intestinal tract to release the thymosin alpha 1. It is prepared from thymosin alpha 1, acrylic resin as enteric material, polyoxyvinyl laurinol ether and laury azazole ketone.

The invention relates to a urine-derived stem cell preparation and a preparation method thereof, and an application of the preparation in preparation of medicines for resisting immune rejection reaction after organ transplantation. The method comprises the steps: selecting clean middle section urine of healthy volunteers; carrying out separated culture and in-vitro amplification by using a culturemedium, and detecting the in-vitro proliferation capacity; detecting the expression level of surface molecular markers by flow cytometry, and detecting the expression level of kidney-associated proteins by immunoblotting; take the third-sixth generations of urinary stem cells identified, meeting the requirements and with confluence of 80% in logarithmic growth phase; preparing the urine-derived stem cell preparation by further digestion, centrifugation and physiological saline resuspension. The urine-derived stem cell preparation has the advantages of wide source, low acquisition cost and high separation efficiency. The urine-derived stem cell preparation can remarkably prolong the survival time of rats after kidney transplantation, reduce the levels of urea nitrogen and creatinine and reduce the infiltration of T cells in kidney tissues; meanwhile, the beating time of a transplant in the mouse heart transplantation can be obviously prolonged.

The invention discloses a peripheral arterial disease diagnosis method based on deep learning. According to the method, tissue blood flow change data of peripheral arterial disease patients and healthy volunteers can be acquired by utilizing the diffusion related spectrum technology against the defects of a traditional method for diagnosing peripheral arterial diseases based on ABI; the tissue blood flow data is trained based on the proposed deep learning network, key features containing peripheral arterial disease information are extracted and are trained to obtain a deep learning network model for diagnosing peripheral arterial diseases, and test set data is input into a peripheral arterial disease diagnosis model for diagnosing, so that peripheral artery diseases are diagnosed. The method overcomes the defects of existing ABI diagnosed peripheral arterial diseases, verifies the feasibility of tissue blood flow measurement for peripheral arterial disease diagnosis, and provides a newtechnology and new method for peripheral arterial disease diagnosis.

The invention discloses a plasma exosome miRNA biological marker and application thereof. The miRNA biological marker includes one or more of miR-15a-5p, miR-106b-5p, and miR-107, and has Application in the preparation of a kit for screening and diagnosing endometrial cancer. In 202 tested samples, the expression of 3 exosomal miRNAs could distinguish endometrial cancer patients from healthy volunteers (AUC=0.873), and it could also be combined with tumor markers CEA and CA125 (AUC=0.904 ) to achieve higher sensitivity and specificity. At the same time, these three miRNAs also play a role in early diagnosis (diagnosis of patients with endometrial cancer), and their combined AUC value in the ROC curve is 0.869, which can be further improved to 0.915 when combined with tumor markers. The kit prepared by the invention is composed of specific amplification primers and general PCR amplification reagents, has high clinical value, and can be effectively used for screening and diagnosis of endometrial cancer, including early screening.

The invention relates to an application of human derived HSF2 as the specific diagnosis molecular marker of ulcerative colitis, and belongs to the technical field of biomedicine. The technical scheme comprises three parts: (1) detecting differential proteins in serums of UC patients and healthy volunteers through a proteomics two-dimensional gel electrophoresis technology and a mass spectrum technology; (2) detecting the HSF2 expression level in colonic mucosa of UC patients in different degrees through an immunohistochemical method; (3) detecting the HSF2 expression level in colonic mucosa of UC patients in different degrees through a real-time quantitative PCR technology and a western blotting technology. 40 UC patient serums and 40 healthy volunteer serums have been compared by the method mentioned above, and the results show that the expression of HSF2 in the UC patient serums prominently increases. Moreover, an immunohistochemical method, a real-time quantitative PCR technology and a western blotting technology are adopted to detect the HSF2 expression in the colonic mucosa of UC patients, and the results show that the HSF2 expression increases as the UC disease goes worse. Thus, the HSF2 can be used as a molecular marker to specifically diagnosing ulcerative colitis.

The present invention relates to a visual function test method based on shielding a glasses. The method is characterized by comprising the following steps of 1) manufacturing the corresponding light filter assemblies; 2) selecting the corresponding shielding pad pasting, wherein the amblyopia depression membranes of a vision grade are selected as the shielding pad pasting; 3) selecting a glasses frame, and determining the concrete sizes of the eyeglass embedment areas of the glasses frame; 4) cutting the sizes of the light filter assemblies to match the eyeglass embedment areas, and tailoring the sizes of the amblyopia depression membranes to be consistent with the sizes of the cut light filter assemblies; 5) embedding and fixing the two light filter assemblies in the eyeglass embedment areas respectively, and pasting a smooth surface of each amblyopia depression membrane and the inner surface of the corresponding light filter assembly as one to manufacture and form the shielding glasses; 6) wearing the manufactured shielding glasses over the eyes of a healthy young volunteer, simulating the function test of a vision disorder state caused by the age-related cataract to the healthy young volunteer, and providing the possible measures for improving the life capability to the old people of specific age according to a test result.

The invention discloses a construction method of a Prevo intestinal type in-vitro simulation model. The fresh feces of the Prevo-intestinal healthy volunteers are diluted with PBS into a fecal suspension by using an automatic intestinal flora in-vitro simulation model apparatus, and the fecal suspension is inoculated into a modified VI medium, and fermentation culture is carried out under conditions of 37 DEG C, pH of 5.2-5.8, magnetic stirring speed of 150 rpm, and supplemented addition with a medium at a rate of 330 ml / 12 h to obtain the Prevo intestinal type in-vitro simulation model. The method finds an important nutritional condition for simulating the Prevo intestinal type in-vitro, explores the physical and chemical conditions in the continuous fermentation process, and can increasethe proportion of Prevo bacteria in a broth to 40% to 80%, and the correlation coefficient between the microbial population in the broth and an original stool sample is about 80%, so that the Prevo intestinal type can be stably simulated in vitro.

Impedance spectroscopy has been proposed as a method of monitoring mucosal injury due to hypoperfusion and ischemia In the critically ill The invention Includes an algorithm developed to calculate the characteristic electrical values best describing human gastnc impedance measurements A database of gastnc spectra was obtained from healthy volunteers, cardiovascular surgery and critically ill patients The gastnc spectrum forms two semi circles in the complex domain, divided into low frequency (F < 10kHz) and high frequency (F >1OkHz) A fitting algopthm was developed based on the Cole model, and central charactepstic parameters were calculated The parameters were validated using the normalized mean squared error and 0 7 % of the spectra were discarded From the expepmental data obtained in humans, the greatest changes observed as the gastnc mucosa becomes ischemic occur at low frequencies, which are specific and sensitive to tissue damage, and vary with the degree of hypoperfusion.

The invention belongs to the field of medical detection, and particularly relates to primers and probes for detecting SARS-CoV-2 and application of the primers and the probes. Four groups of primers and probes are designed, the SARS-CoV-2 is detected by adopting a common TaqMan-MGB probe method, and the primers and probes can be used for detecting a SARS-CoV-2 wild type, a SARS-CoV-2 variant, a SARS-CoV-2 B.1.617 subtype variant and a SARS-CoV-2 B.1.617.2 subtype variant. Pseudovirus test results show that the sensitivity of a reagent can reach 500 copies / mL. No non-specific amplification exists in detection of 10 healthy volunteers and 4 common other respiratory pathogens, and the primer and probe combination and the reagent have good specificity.

The invention discloses an application of BAMBI as a nasopharyngeal carcinoma maker. Through experiment researches by an applicant and a whole team for three years, researches on tissues and serums of 38 nasopharyngeal carcinoma patients, 12 chronic nasopharyngitis patients and 49 healthy volunteers are carried out, the researches show that the nasopharyngeal tissue BAMBI expression amount of the nasopharyngeal carcinoma patients is obviously increased, the expression amount of nasopharyngitis (nasopharyngitis is common benign disease) is relatively low, wherein p equals 0.0038, and the difference between nasopharyngeal carcinoma and nasopharyngitis is obvious. The serum BAMBI of the nasopharyngeal carcinoma patients is obviously increased, through statistical analysis, t equals 2.639, and p equals 0.012. No matter in nasopharyngeal carcinoma tissue or nasopharyngeal carcinoma serum, BAMBI presents up-regulated expression, so that the detection of BAMBI can be taken as a nasopharyngeal carcinoma molecular screening index.

The invention discloses an application of lncRNA (long noncoding RNA)-MIR3945HG V1 in diagnosis of smear and culture negative pulmonary tuberculosis. The invention finds that up-regulated expression of MIR3945HG V1 is caused by MTB (mycobacterium tuberculosis) infection with Mphi; results of PBMC detection of 30 patients with smear and culture negative pulmonary tuberculosis show that the expression levels of MIR3945HG V1 of the patients are obviously higher than those of healthy volunteers; an analysis result of a receiver operating characteristic curve shows that MIR3945HG V1 is expected to become a novel target for diagnosis of smear and culture negative pulmonary tuberculosis. Uninfected people and the patients with smear and culture negative pulmonary tuberculosis can be distinguished effectively by detecting the expression level of MIR3945HG V1.

The invention relates to the field of clinical medical treatment, in particular to an intestinal microflora kit for diagnosis of coronary heart disease and application thereof. A first reagent is a water-soluble primer with gene sequences of 5'-AGAGTTTGATCATGGCTC-3' and 5'-CCGTCAATTCCTTTGAGTTT-3'; a second reagent is a pGEM-T easy vector plasmid. The intestinal microflora kit has the advantages that by performing PCR (polymerase chain reaction) amplification on a metabolism sample, introducing the pGEM-T easy vector plasmid and transferring DH5alpha competent cells, the obviously different organisms exist in the intestines of a healthy volunteer and a patient with the coronary heart disease, and the obvious difference may be used as the feature index for screening the coronary heart disease; after study, a new method is provided for the screening and diagnosis of the coronary heart disease; the great social meaning and economic benefit are realized.

The invention discloses applications of lncRNA-MIR3945HG V2 in diagnosis of mycobacterium tuberculosis negative pulmonary tuberculosi. The result shows that after MTB is infected with macrophages, the expression of MIR3945HG V2 is up-regulated; the detection result for PBMC of 30 cases of patients suffering from mycobacterium tuberculosis negative pulmonary tuberculosis shows that the expression level of MIR3945HG V2 is obviously higher than that of healthy volunteers; the analysis result for the receiver operating characteristic curve shows that MIR3945HG V2 is expected to become the novel target for diagnosing the mycobacterium tuberculosis negative pulmonary tuberculosis. By detecting the expression level of lncRNA-MIR3945HG V2, the not infected people can be effectively distinguished from the patients suffering from mycobacterium tuberculosis negative pulmonary tuberculosis.

The invention discloses a killing method for identifying gamma delta T cells simply and rapidly. The method comprises the following steps: firstly, healthy volunteer peripheral blood is collected, separation is carried out by utilization of a human lymphocyte separating medium, mononuclear cells are obtained, phosphate antigens HMBPP with 10-30ng / ml and rhIL-2 factors with 500-1000 IU / ml are added, PBMC induction into gamma delta T cells is carried out and amplification culture is carried out; secondly, after culture is carried out for 8-10 days, gamma delta T cells are subjected to detection of destruction experiments, the living cell dye calcein-AM is employed to dye tumor cells, the cell density during dyeing is controlled at 10<5>-10<7> / ml; thirdly, the tumor cells after dyeing and the gamma delta T cells are cultured together for a period of time, the cells are collected, propidium iodide is added for dyeing before detection, finally, a flow cytometer is employed to detect cell death amount, and the cell killing rate is obtained. Through the method that the cell killing efficiency can be detected rapidly through a flow cytometer, limitation conditions of traditional 51Cr radioactive substance pollution and low sensitivity of MTT and LDH are overcome.

The invention relates to a method for determining and screening differential metabolites of laryngeal cancer serum based on an inverted phase chromatography time-of-flying mass spectrum. The method is characterized by comprising the steps of settling protein from serum by virtue of an organic solvent, namely methanol, carrying out centrifugation and vacuum centrifugal drying, redissolving the serum into 200 microliters of pure water, introducing the solution into an inverted phase chromatography time-of-flying mass spectrometer for determination, and carrying out peak alignment, correction and standardization, multivariate statistics analysis and spectrum library searching, so as to find differential metabolites in serums of laryngeal cancer volunteers and healthy volunteers. The method is a brand-new method for identifying the differential metabolites in the serum, and the variation conditions of the serum metabolites of laryngeal cancer patients can be reflected by the differential metabolites, so that the method will contribute to the diagnosis, clinic treatment and prognosis of the laryngeal cancer and the research of pathogenesis of the laryngeal cancer.

The invention discloses application of CD1c to smear and culture negative pulmonary tuberculosis diagnosis. It is found that after MTB is infected with DCs, CD1c expression is down-regulated; in DCs coming from PBMCs of a smear and culture negative pulmonary tuberculosis patient, compared with a healthy volunteer, the expression level of CD1c is remarkably down regulated; the detection result of PBMCs of 119 smear and culture negative pulmonary tuberculosis patients also shows that the expression level of CD1c is remarkably lower than that of a healthy volunteer; the receiver operation characteristic curve analysis result shows that it is hopeful that CD1c becomes a new target spot of smear and culture negative pulmonary tuberculosis diagnosis. By detecting the express level of CD1c mRNA, non-infected people and smear and culture negative pulmonary tuberculosis patients can be effectively differentiated.

The invention discloses a marker for digestive system cancer detection and application of the marker. The marker is a combination of Vimentin and CD11b. The expression conditions of the marker in different individuals show the special phenomena of ultrahigh expression in peripheral blood of a cancer patient, higher expression in peripheral blood of an early cancer patient and almost no expressionin peripheral blood of a healthy volunteer, and the marker can be used for digestive system tumor early screening and solid tumor treatment dominant population including gastric cancer and evaluatingthe treatment effect.